| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vitro |
In HepG2 cells with stable GBA1 knockdown, the levels of GlcCer (d18:1/18:0) in the whole cell and plasma membrane were elevated, which was the most significantly elevated GlcCer subtype in the plasma membrane and formed an endogenous in situ interaction with the Wnt co-receptor LRP6 [1]. Wild-type Penicillium digitatum produces GlcCer (d18:1/18:0) for 4 days, which is absent in PdGcs1 deletion mutants but can be restored in PdGcs1 complementary mutants, which confirms that PdGcs1 encodes glucosylceramide synthase responsible for its biosynthesis [3]. In PdGcs1-deficient Penicillium digitatum, the lack of GlcCer (d18:1/18:0) inhibits vegetative growth, sporulation and conidial germination, while these defects can be completely restored in complementary strains [3]. Wild-type Penicillium digitatum PdKH8 produces GlcCer (d18:1/18:0) (4 days), which is absent in the PdGcs1 deletion mutant but is restored in the PdGcs1 complement mutant [4]. Normal vegetative growth, sporulation and conidial germination of Penicillium digitatum require GlcCer (d18:1/18:0) (5 days (radial growth and sporulation); 8, 12, 16, 24 hours (conidial germination)), as evidenced by impaired growth, reduced sporulation and delayed germination in the PdGcs1 deletion mutant (which does not produce GlcCer (d18:1/18:0)) and the restoration of these traits in the complement mutant [4].
|
|---|---|
| ln Vivo |
In the corpus callosum of copper azole-induced demyelinating mice, GlcCer (d18:1/18:0) was significantly reduced and showed excellent discrimination ability against demyelinating models (AUC0-t = 0.990)[5].
|
| References |
|
| Molecular Formula |
C42H81NO8
|
|---|---|
| Molecular Weight |
728.09
|
| CAS # |
95119-86-1
|
| Related CAS # |
C18 Glucosyl(ß) ceramide-d5
|
| Appearance |
White to off-white solid
|
| SMILES |
CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](NC(CCCCCCCCCCCCCCCCC)=O)CO[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O)CO
|
| Synonyms |
C18 Glucosyl(β) ceramide (d18:1/18:0); D-glucosyl-β-1,1' N-stearoyl-D-erythro-sphingosine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~2.5 mg/mL (~3.43 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3735 mL | 6.8673 mL | 13.7346 mL | |
| 5 mM | 0.2747 mL | 1.3735 mL | 2.7469 mL | |
| 10 mM | 0.1373 mL | 0.6867 mL | 1.3735 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
